XNASPTIX
Market cap3mUSD
Dec 24, Last price
0.49USD
1D
-8.01%
1Q
-15.72%
Name
Protagenic Therapeutics Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.11%
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L+38.84%
CFO
-4m
L+85.76%
Earnings
Mar 31, 2025
Profile
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑06 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 4,555 | 3,558 | 4,140 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,555) | (3,558) | (4,140) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | 46 | 464 | |||||||
Tax Rate | |||||||||
NOPAT | (4,555) | (3,604) | (4,604) | ||||||
Net income | (5,000) 38.84% | (3,602) -27.78% | (4,987) 78.42% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 11,708 | ||||||||
BB yield | -57.35% | ||||||||
| Debt | |||||||||
Debt current | 344 | ||||||||
Long-term debt | 318 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | 1,014 | ||||||||
Net debt | (4,056) | (7,634) | (10,053) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (3,704) | (1,994) | (2,799) | ||||||
CAPEX | (150) | (2) | |||||||
Cash from investing activities | 4,775 | 1,597 | (9,910) | ||||||
Cash from financing activities | 12,578 | ||||||||
FCF | (4,677) | (3,606) | (4,604) | ||||||
| Balance | |||||||||
Cash | 4,056 | 7,979 | 10,371 | ||||||
Long term investments | |||||||||
Excess cash | 4,056 | 7,979 | 10,371 | ||||||
Stockholders' equity | (30,891) | (26,454) | (22,468) | ||||||
Invested Capital | 34,559 | 33,716 | 32,729 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 4,345 | 4,318 | 3,685 | ||||||
Price | 0.99 -38.13% | 1.60 -71.12% | 5.54 | ||||||
Market cap | 4,301 -37.74% | 6,909 -66.16% | 20,416 | ||||||
EV | 245 | (726) | 10,363 | ||||||
EBITDA | (4,527) | (3,558) | (3,713) | ||||||
EV/EBITDA | 0.20 | ||||||||
Interest | 137 | 497 | |||||||
Interest/NOPBT | |||||||||